Centanafadine clinical trials
Also written EB-1020.
Includes 2 studies of Centanafadine hydrochloride.
How each study uses centanafadine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the centanafadine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 24 Jul 2026 · SIMTRIYO · NDA 218145 (FDA, Drugs@FDA; as centanafadine hydrochloride)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 5 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 25 · Other 0
Otsuka Pharmaceutical Development & Commercialization, Inc. (21) · Otsuka Pharmaceutical Co., Ltd. (4)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 3 in phase 3
Studies that test centanafadine, phase 3 first.
- May 2027A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional DysregulationPhase 3 · Otsuka Pharmaceutical Development & Commercialization, Inc.
- Aug 2027A Long-term Trial of EB-1020 in Pediatric Patients With ADHDPhase 3 · Otsuka Pharmaceutical Co., Ltd.
- Aug 2027A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHDPhase 2/3 · Otsuka Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses centanafadine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 25
- A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional DysregulationRecruitingPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT07759154Written as Centanafadine XRHow we know
- A Long-term Trial of EB-1020 in Adult Patients With ADHDRecruitingPhase 3Otsuka Pharmaceutical Co., Ltd.NCT06926829Written as EB-1020 (Centanafadine) 164.4 mgHow we know
- Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD PatientsRecruitingPhase 2/3Otsuka Pharmaceutical Co., Ltd.NCT06931080Written as EB-1020 (Centanafadine) 164.4 mgHow we know
- A Long-term Trial of EB-1020 in Pediatric Patients With ADHDRecruitingPhase 3Otsuka Pharmaceutical Co., Ltd.NCT07087327Written as EB-1020 (Centanafadine) low doseHow we know
- A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHDRecruitingPhase 2/3Otsuka Pharmaceutical Co., Ltd.NCT07086313Written as EB-1020 (Centanafadine) low doseHow we know
- A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.CompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05279313Written as Centanafadine HydrochlorideHow we know
- Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive DisorderCompletedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05536414Written as CentanafadineHow we know
- P3b Short-term Study of CTN in Patients With ADHD and Comorbid AnxietyCompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT06973577Written as CentanafadineHow we know
- A Trial to Assess How Centanafadine Interacts With Stimulants in the BodyCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT07314333Written as CentanafadineHow we know
- A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020CompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT01744808Written as EB-1020 IRHow we know
- A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant UsersCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02144415Written as EB-1020 400 mgHow we know
- A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)CompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05428033Written as centanafadine capsuleHow we know
- Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy SubjectsCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT07486895Written as CentanafadineHow we know
- A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of CentanafadineCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT07465731Written as Centanafadine SRHow we know
- A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood LevelsCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT07253441Written as CTN XR (TBM)How we know
- A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating DisorderCompletedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05113953Written as CentanafadineHow we know
- Efficacy of Centanafadine SR as a Potential Smoking Cessation TreatmentCompletedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05066724Written as CentanafadineHow we know
- A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity DisorderCompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT03605849Written as Centanafadine SRHow we know
- A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity DisorderCompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05257265Written as Centanafadine HydrochlorideHow we know
- A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity DisorderCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT04786730Written as CentanafadineHow we know
Codes
What other systems call centanafadine · ClinicalTrials.gg INT006113
- UNII (FDA) D2A6T4UH9CCENTANAFADINEConfirmed FDA, Wikidata
- Wikidata Q27276010centanafadineConfirmed FDA, Wikidata
- NCI Thesaurus C171666CentanafadineOne source FDA
- DrugBank DB14841One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | D2A6T4UH9C | CENTANAFADINE | Confirmed FDA, Wikidata |
| Wikidata | Q27276010 | centanafadine | Confirmed FDA, Wikidata |
| NCI Thesaurus | C171666 | Centanafadine | One source FDA |
| DrugBank | DB14841 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.